Kits for local delivery of water soluble agents and methods of use

1. A kit comprising:

an implantable pouch comprising a substrate defining a pocket configured for disposal of an implantable medical device, the pouch comprising a polymer that coats at least a portion of the substrate, the polymer comprising an active agent that is configured to elute over time; and

a hemostatic agent,

wherein the hemostatic agent is separate from the pouch,

wherein the pouch comprising the polymer is disposed in a first package and the hemostatic agent is disposed in a second package that is separate from the first package.

2. A kit as recited in claim 1 , wherein the hemostatic agent comprises a solution or suspension that includes at least one of epinephrine, tranexamic acid, chitosan, oxidized regenerated cellulose, thrombin, protamine, norepinephrine, desmopressin, lysine analogs, collagen, gelatin, polysaccharide spheres, mineral zeolite, calcium salt, bovine thrombin, pooled human thrombin, recombinant thrombin, gelatin and thrombin, collagen and thrombin, cyanacrylate, fibrin glue, polyethylene glycol, peptide, and glutaraldehyde.

3. A kit as recited in claim 2 , wherein the implantable medical device is selected from the group consisting of vascular devices, stents, catheters, valves, embolic protection filters, vena cava filters, aneurysm exclusion devices, pacemakers, artificial hearts, cardiac jackets, heart assist devices, implantable defibrillators, subcutaneous implantable defibrillators, implantable monitors, implanted medical device power supplies, peripheral cardiovascular devices, atrial septal defect closures, left atrial appendage filters, valve annuloplasty devices, mitral valve repair devices, vascular intervention devices, ventricular assist pumps, implantable pain pumps, neuromodulators, and vascular access devices.

4. A kit as recited in claim 1 , wherein the first package is a sterile package and the second package is a sterile package.

5. A kit as recited in claim 1 , wherein the polymer comprises a tyrosine-derived polyesteramide.

6. A kit as recited in claim 5 , wherein the tyrosine-derived polyesteramide is a member of the P22 family of tyrosine-derived polyesteramides.

7. A kit as recited in claim 6 , wherein a percentage of free acid in the P22 family of tyrosine-derived polyesteramides ranges from about 5% to about 100%.

8. A kit as recited in claim 1 , wherein the active agent is selected from the group consisting of antibiotics, antiseptics, and disinfectants.

9. A kit as recited in claim 1 , wherein the active agent comprises a combination of minocycline and rifampin.

10. A kit as recited in claim 4 , further comprising the implantable medical device, the implantable medical device being selected from the group consisting of vascular devices, stents, catheters, valves, embolic protection filters, vena cava filters, aneurysm exclusion devices, pacemakers, artificial hearts, cardiac jackets, heart assist devices, implantable defibrillators, subcutaneous implantable defibrillators, implantable monitors, implanted medical device power supplies, peripheral cardiovascular devices, atrial septal defect closures, left atrial appendage filters, valve annuloplasty devices, mitral valve repair devices, vascular intervention devices, ventricular assist pumps, implantable pain pumps, neuromodulators, and vascular access devices.

11. A kit as recited in claim 10 , wherein the polymer comprises a tyrosine-derived polyesteramide.

12. A kit as recited in claim 1 , wherein the active agent comprises a combination of minocycline and rifampin.

13. A kit comprising:

an implantable medical device;

a pouch comprising a mesh substrate defining a pocket configured for disposal of an implantable medical device, the pouch comprising a polymer that coats at least a portion of the substrate, the polymer comprising an active agent that is configured to elute over time, the polymer comprising a tyrosine-derived polyesteramide, the active agent comprising a combination of minocycline and rifampin; and

a hemostatic agent,

wherein the pouch is disposed in a first package and the hemostatic agent is disposed in a second package that is separate from the first package.